ISSN: 2320-5407 Int. J. Adv. Res. 8(01), 642-644 642 Journal Homepage: -www.journalijar.com Article DOI:10.21474/IJAR01/10342 DOI URL: http://dx.doi.org/10.21474/IJAR01/10342 RESEARCH ARTICLE A BRIEF REVIEW ON TAFENOQUINE IN RELAPSE MALARIA Mounika Puppala 1 , Ramam Sripada 2 , Keerthi Chowdary Yelavarthy 1 , Himabindu Mylapalli 2 , Sudeepthi Padala 2 , Sireesha Maram 2 , Visalakshi Kasilanka 2 and Dasaratha Dhanaraju Magharla 2 1. Scientific analysts, Molecular connections private limited, Bangalore, Karnataka, India. 2. Department of Pharmacy Practice, GIET School of Pharmacy, Rajahmundry, Andhra Pradesh, India. …………………………………………………………………………………………………….... Manuscript Info Abstract ……………………. ……………………………………………………………… Manuscript History Received: 27 November 2019 Final Accepted: 30 December 2019 Published: January 2020 Key words:- Malaria, Primaquine, Tafenoquine Malarial relapse is the reactivation of the hypnozoite form of parasite in the liver cells. It is the reappearance of the symptoms after elimination of the parasite from the blood where the parasite still persists as the dormant hypnozoites in the liver cells. It usually occurs between 8-24 weeks after the elimination of parasite from the blood and is most common among the individuals with P.vivax and P.ovale infections. Drugs having both hypnozoiticidal and schizonticidal effects are used in the treatment of relapse malaria. Primaquine is the only drug which shows both schizonticidal and hypnozoiticidal effect in treating the relapse malaria. Primaquine has a long term chemoprophylaxis with adverse effect profile hence, there is a requirement for a drug with long acting hypnozoiticidal action in a single dose where, tafenoquine serves the need in providing a short-course treatment regimen for the radical cure instead of prescribing a 14-day course of primaquine. In this article, we mainly reviewed the approval, adverse effects profile, contraindications and precautions to be taken during the usage of Tafenoquine. In India, clinical trials are still under progress and yet to be approved to replace the current 14 day treatment regimen of primaquine. In order to cope up with the challenge in the treatment of relapse malaria, tafenoquine offers a ray of hope in dealing the relapse malaria effectively. Copy Right, IJAR, 2020,. All rights reserved. …………………………………………………………………………………………………….... Introduction:- Malaria is a life threatening disease caused by parasites that are transmitted to the people through the bite of infected female anopheles mosquito. It usually occurs due to Plasmodium species that include P.vivax, P.falciparum, P.malariae & P.ovale and among these species, P.falciparum & P.ovale are predominant. About 99.7% of malaria cases in African region, 62.8% in South-East Asia, 69% in Eastern Mediterranean and 71.9% in Western Pacific were caused due to Plasmodium falciparum. Plasmodium vivax is the most prominent parasite in America causing 74% of the total malaria cases. In the year 2017, it was estimated that there were about 219 million malarial cases and 4,35,000 deaths occurred due to malaria among 87 countries. 1 The parasite which enters into the blood stream of a healthy individual attacks the liver cells and the red blood cells. The signs & symptoms usually may appear after 10-15 days of the bite of the infected mosquito. The most common signs & symptoms of malaria are headache, fever, chills, muscle pain, fatigue, nausea, vomiting, cough, abdominal Corresponding Author:-Ramam Sripada Address:-Department of Pharmacy Practice, GIET School of Pharmacy, Rajahmundry, Andhra Pradesh, India. .